에 대한 최신 뉴스 Vaccinex (NASDAQ:VCNX) 주식

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

<p>During the last three months, 10 analysts shared their evaluations of Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Freshworks, presenting an average target of $17.4, a high estimate of $24.00, and a low estimate of $11.00. This upward trend is evident, with the current average reflecting a 3.02% increase from the previous average price target of $16.89.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734436809_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of Freshworks by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Freshworks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Freshworks compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Freshworks's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Freshworks's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FRSH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Freshworks analyst ratings.</strong></a></p>
<h2>All You Need to Know About Freshworks</h2>
<p>Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.</p>
<h3>A Deep Dive into Freshworks's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Freshworks showcased positive performance, achieving a revenue growth rate of <strong>21.51%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Freshworks's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-16.06%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-2.66%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.92%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Freshworks's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

FRSH

Forecasting The Future: 10 Analyst Projections For Freshworks

<p>JP Morgan  analyst Allen Gong   downgrades TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Overweight to Neutral and lowers the price target from $116 to $75.</p>


News

Downgrades

Price Target

TMDX

JP Morgan Downgrades TransMedics Gr to Neutral, Lowers Price Target to $75

<p>JP Morgan  analyst Anthony Paolone   upgrades AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) from Neutral to Overweight and raises the price target from $247 to $262.</p>


Upgrades

JP Morgan Upgrades AvalonBay Communities to Overweight, Raises Price Target to $262

<p>JP Morgan  analyst Anthony Paolone   upgrades Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) from Underweight to Neutral and raises the price target from $14 to $17.</p>


JP Morgan Upgrades Veris Residential to Neutral, Raises Price Target to $17

Guidance

Pfizer Reaffirms FY24 Outlook For Revenue Of $61B – $64B (Est $62.974B), Adj EPS Of $2.75 – $2.95 (Est $2.92)

<p>Stifel  analyst Adam Borg   upgrades Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Hold to Buy and raises the price target from $95 to $136.</p>


Stifel Upgrades Cloudflare to Buy, Raises Price Target to $136

Endeavour Silver Says Guanaceví Processing Resumed To Full Capacity This Week After Trunnion Failure In August

<ul>
<li>The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels, both essential for brain function and metabolic health.</li>
<li>At the end of the one-week treatment period, patients receiving PKU GOLIKE as the last daily protein substitute dose showed a statistically significant reduction in blood Phe levels compared to those receiving standard amino acid substitutes (P=0.0002) and a statistically significant increase in blood Tyr levels (P=0.0113). Compared to baseline levels measured prior to the start of treatment, the PKU GOLIKE group achieved an average 17.8% reduction in blood Phe levels (P=0.0484) and an average 33.8% increase in blood Tyr levels (P=0.0008) upon awakening after the overnight fasting period. In comparison, when treated with standard amino acid protein substitutes, the same patients experienced an average 27.6% increase in blood Phe levels (P=0.0063) and no significant improvement in blood Tyr levels. Blood sample analysis at three early morning time points across the two groups revealed no significant differences in peak Phe levels upon reawakening in either group.</li>
</ul>


Biotech

Health Care

General

ETON

Eton Pharmaceuticals Announced The Full Readout From The Clinical Trial Evaluating PKU GOLIKE As A Protein Substitute For Phenylketonuria In Patients During Prolonged Fasting Periods

<p>Piper Sandler  analyst Patrick Moley   initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Overweight rating and announces Price Target of $33.</p>


Initiation

Piper Sandler Initiates Coverage On Hut 8 with Overweight Rating, Announces Price Target of $33

Pfizer Says First Phase Of Manufacturing Optimization Program On Track To Deliver Initial Net Cost Savings In The Latter Part Of 2025

Pfizer Says It Achieved Goal Of $4B In Net Cost Savings Through 2024; Anticipates Additional $500M In Savings In 2025 From Ongoing Cost Realignment Program

Management

AIRS

AirSculpt Technologies Has Appointed Yogi Jashnani As Chief Executive Officer And A Member Of The Board Of Directors. He Succeeds Dennis Dean, Interim CEO And CFO Who Will Continue As CFO, All Effective January 7, 2025

<p>Jefferies  analyst James Heaney   downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Buy to Hold and lowers the price target from $40 to $32.</p>


MTCH

Jefferies Downgrades Match Group to Hold, Lowers Price Target to $32

Pfizer Expects FY25 Revenue Of $61B - $64B  (Est $63.276B), Adjusted EPS Of $2.80 - $3.00 (Est $2.90)

<p>If approved, clesrovimab has the potential to be available to help address the burden of RSV disease in the U.S. in time for the 2025-26 season</p>


Large Cap

The FDA Has Accepted The Biologics License Application For Merck's Clesrovimab (MK-1654) To Protect Infants From Respiratory Syncytial Virus Disease During Their First Season, With Prescription Drug User Fee Act Or Target Action, Date Of June 10, 2025

<p>Piper Sandler  analyst Patrick Moley   initiates coverage on Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) with a Overweight rating and announces Price Target of $23.</p>


RIOT

Piper Sandler Initiates Coverage On Riot Platforms with Overweight Rating, Announces Price Target of $23

<p>Janney Montgomery Scott  analyst Michael Gaugler   initiates coverage on Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Neutral rating and announces Price Target of $73.</p>


Janney Montgomery Scott Initiates Coverage On Spire with Neutral Rating, Announces Price Target of $73

Pfizer Provides Its Full-year 2025 Guidance And Reaffirms Its Full-year 2024 Guidance

<p>Piper Sandler  analyst Patrick Moley   initiates coverage on MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Overweight rating and announces Price Target of $34.</p>


MARA

Piper Sandler Initiates Coverage On MARA Holdings with Overweight Rating, Announces Price Target of $34

<p>Compass Point  analyst Casey Alexander   upgrades Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) from Sell to Neutral and announces $8.25 price target.</p>


HRZN

Compass Point Upgrades Horizon Tech Finance to Neutral, Announces $8.25 Price Target

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pe...

Vaccinex Provides Update on Alzheimer's Treatment Trial

Vaccinex says Alzheimer's candidate buoyed by additional early-stage data

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Vaccinex</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/"><strong>VCNX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Vaccinex reported earnings per share of -$3.10.</li><li>The company reported revenue of $232,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/vcnx-stock-earnings-vaccinex-for-q2-of-2024/">VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a director of Vaccinex, Inc., effectiv...

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

Vaccinex exercises warrants for proceeds of $6.2M

Vaccinex files for secondary stock offering

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study ...

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vacci...

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

Reports Q3 revenue $52,000 vs. $20,000 last year. Cash and cash equivalents and marketable securities on September 30, 2024, were $2.9 million, as ...

Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year

Vaccinex reports Q3 figures

VCNX

Press Releases

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Financing

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Comments

Vaccinex

뉴스

에 대한 최신 뉴스 Vaccinex (NASDAQ:VCNX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌